Findings

What do systematic reviews say?

10 questions · 10 findings · 5 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 30%GRADE not reported 0 · 0%Very low 0 · 0%Low 5 · 50%Moderate 2 · 20%High 0 · 0%

Mesalamine vs placebo

Adverse events · Patients with collagenous colitis

Mesalamine showed no clear difference in adverse events compared with placebo (low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 1.26 [0.84, 1.88]
1 study · 62 participants
Low

Mesalamine vs placebo

Serious adverse events · Patients with collagenous colitis

Mesalamine showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 4.44 [0.49, 40.29]
1 study · 62 participants
Low

Mesalamine vs placebo

Withdrawals due to adverse events · Patients with collagenous colitis

Mesalamine showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 5.92 [0.7, 49.9]
1 study · 62 participants
Low

Enteral nutrition vs mesalamine

Adverse events · Participants with Crohn's disease in remission

The review found no eligible studies for this question.

1 finding from 1 review

Enteral nutrition for maintenance of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Enteral nutrition vs mesalamine

Serious adverse events · Participants with Crohn's disease in remission

The review found no eligible studies for this question.

1 finding from 1 review

Enteral nutrition for maintenance of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Budesonide vs mesalamine

Serious adverse events · Adult patients with active ulcerative colitis

Budesonide showed no clear difference in serious adverse events compared with mesalamine (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.75 [0.17, 3.28]
1 study · 254 participants
Low

Budesonide vs mesalamine

Adverse events Gross 2011 · Adult patients with active ulcerative colitis

Budesonide showed no clear difference in adverse events Gross 2011 compared with mesalamine (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.05 [0.73, 1.5]
1 study · 343 participants
Moderate

Enteral nutrition vs mesalamine

Withdrawals due to adverse events · Participants with Crohn's disease in remission

The review found no eligible studies for this question.

1 finding from 1 review

Enteral nutrition for maintenance of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Budesonide 9 mg vs mesalamine

Withdrawals due to adverse events · Patients with active Crohn's disease

Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with mesalamine (low certainty).

1 finding from 1 review

Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 0.43 [0.18, 1.03]
2 studies · 489 participants
Low

5‐ASA vs control (all trials)

Number of participants with adverse events (epigastric pain, nausea, diarrhoea) · patients with the need for management of diverticulitis

5‐ASA showed no clear difference in number of participants with adverse events (epigastric pain, nausea,… compared with control (all trials) (moderate certainty).

1 finding from 1 review

Mesalamine (5‐ASA) for the prevention of recurrent diverticulitis 2017 · Cochrane Headline outcomes only
RR 0.98 [0.91, 1.06]
5 studies · 1421 participants
Moderate